Academic Journal
Comparative assessment of model for end-stage liver disease, modified model for end-stage liver disease including sodium, and Maddrey's discriminant function in alcoholic hepatitis mortality: a systematic review and diagnostic meta-analysis.
| Τίτλος: | Comparative assessment of model for end-stage liver disease, modified model for end-stage liver disease including sodium, and Maddrey's discriminant function in alcoholic hepatitis mortality: a systematic review and diagnostic meta-analysis. |
|---|---|
| Συγγραφείς: | Tschaen JM; Higher School of Sciences of the Holy House of Mercy of Vitória, Vitória., Fernandes MV; Hepatology Post-Graduation Program, Porto Alegre Health Science's Federal University, Porto Alegre., Holanda EU; University Center Christus (Unichristus), Ceará., Kleimmann RF; Federal University of Paraná (UFPR), Paraná., Fondelli AA; University of Taubate (UNITAU), São Paulo., Pauperio PM; Bahiana School of Medicine and Public Health, Bahia, Brazil., D'Amico F; Gastroenterology and Endoscopy Unit, IRCCS San Raffaele Hospital, Milan, Italy. |
| Πηγή: | European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2026 Jul 01; Vol. 38 (7), pp. 783-790. Date of Electronic Publication: 2026 Jan 15. |
| Τύπος έκδοσης: | Journal Article; Systematic Review; Meta-Analysis; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9000874 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5687 (Electronic) Linking ISSN: 0954691X NLM ISO Abbreviation: Eur J Gastroenterol Hepatol Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Lippincott Williams And Wilkins Original Publication: [London, UK ; Philadelphia, PA, USA] : Current Science, c1989- |
| Ιατρικοί όροι (MeSH): | Hepatitis, Alcoholic*/mortality , Hepatitis, Alcoholic*/diagnosis , Hepatitis, Alcoholic*/blood , Sodium*/blood , End Stage Liver Disease*/mortality , End Stage Liver Disease*/diagnosis , End Stage Liver Disease*/blood , Decision Support Techniques*, Biomarkers/blood ; Humans ; Predictive Value of Tests ; Prognosis ; Discriminant Analysis ; Severity of Illness Index ; Reproducibility of Results ; Risk Factors ; Time Factors |
| Περίληψη: | Alcoholic hepatitis is a form of acute liver injury with significant morbidity and mortality. Several scoring systems have been developed and used to predict mortality, including Maddrey's discriminant function (MDF), model for end-stage liver disease (MELD), and modified MELD including sodium (MELD-Na). We conducted a systematic review of Pubmed, Embase, and Cochrane Library to compare the accuracy of these scores in alcoholic hepatitis mortality prediction. The pooled sensitivity and specificity of MDF for mortality prediction in 28 days were 0.898 [95% confidence interval (CI) 0.777-0.957, I2 = 0%] and 0.370 (95% CI: 0.271-0.482, I2 = 78%), respectively; in 90 days, they were 0.898 (95% CI: 0.799-0.951, I2 =21%) and 0.346 (95% CI: 0.246-0.463, I2 = 88%), respectively. The pooled sensitivity and specificity of MELD for mortality prediction in 28 days were 0.862 (95% CI: 0.755-0.926, I2 = 0%) and 0.697 (95% CI: 0.552-0.812, I2 = 82%), respectively; in 90 days, they were 0.884 (95% CI: 0.802-0.935, I2 = 21%) and 0.557 (95% CI: 0.300-0.787, I2 = 96%), respectively. The pooled sensitivity and specificity of MELD-Na for mortality prediction in 28 days were 0.652 (95% CI: 0.429-0.823, I2 = 79%) and 0.757 (95% CI: 0.666-0.830, I2 = 91%), respectively; in 90 days, they were 0.701 (95% CI: 0.661-0.737, I2 = 53%) and 0.816 (95% CI: 0.711-0.888, I2 = 94%), respectively. No significant statistical difference was observed when comparing area under the curve of these scores. (Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Karsan HA, Parekh S. Management of alcoholic hepatitis: current concepts. World J Hepatol 2012; 4:335–341. World Health Organization. Alcohol. 2024. https://www.who.int/news-room/fact-sheets/detail/alcohol . [Accessed 6 October 2024]. Goyal SK, Dixit VK, Jain AK, Mohapatra PK, Ghosh JK. Assessment of the model for end-stage liver disease (MELD) score in predicting prognosis of patients with alcoholic hepatitis. J Clin Exp Hepatol 2014; 4:19–24. Kim HY, Kim CW, Kim TY, Song DS, Sinn DH, Yoon EL, et al.; Korean Acute-on-Chronic Liver Failure Study Group. Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis. World J Gastroenterol 2016; 22:9205–9213. Kadian M, Kakkar R, Dhar M, Kaushik RM. Model for end-stage liver disease score versus Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis. J Gastroenterol Hepatol 2014; 29:581–588. Ali S, Hussain S, Hair M, Shah AA. Comparison of Maddrey discriminant function, Child-Pugh score and glasgow alcoholic hepatitis score in predicting 28-day mortality on admission in patients with acute hepatitis. Ir J Med Sci 2013; 182:63–68. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76:1021–1029. Lafferty H, Stanley AJ, Forrest EH. The management of alcoholic hepatitis: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2013; 38:603–610. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365:1790–1800. Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011; 86:37–42. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al.; PROBAST Group. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med 2019; 170:51–58. Amieva-Balmori M, Mejia-Loza SMI, Ramos-González R, Zamarripa-Dorsey F, García-Ruiz E, Pérez Y López N, et al. Model for end-stage liver disease-Na score or Maddrey discrimination function index, which score is best? World J Hepatol 2015; 7:2119–2126. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2:2. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Vasilieva L, Archimandritis AJ. Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J Gastroenterol 2006; 12:4020–4025. Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: a global study. Am J Gastroenterol 2022; 117:301–310. Božin T, Rob Z, Lucijanić M, Čmarec Buhin L, Grgurević I. Comparison of prognostic scores for alcoholic hepatitis: a retrospective study. Croat Med J 2021; 62:17–24. Papastergiou V, Tsochatzis EA, Pieri G, Thalassinos E, Dhar A, Bruno S, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther 2014; 39:721–732. Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, et al. Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2022; 20:e289–e297. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652–1660. Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology 2017; 66:1464–1473. |
| Contributed Indexing: | Keywords: Maddrey’s discriminant function; alcoholic hepatitis; model for end-stage liver disease; modified model for end-stage liver disease including sodium; mortality |
| Substance Nomenclature: | 9NEZ333N27 (Sodium) 0 (Biomarkers) |
| Entry Date(s): | Date Created: 20260128 Date Completed: 20260529 Latest Revision: 20260601 |
| Update Code: | 20260601 |
| DOI: | 10.1097/MEG.0000000000003129 |
| PMID: | 41605428 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!